Growth Metrics

Rigel Pharmaceuticals (RIGL) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $27.9 million.

  • Rigel Pharmaceuticals' Income towards Parent Company rose 12461.96% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 281795.93%. This contributed to the annual value of $17.5 million for FY2024, which is 16961.06% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Income towards Parent Company stood at $27.9 million, which was up 12461.96% from $59.6 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Income towards Parent Company registered a high of $59.6 million during Q2 2025, and its lowest value of -$27.4 million during Q1 2022.
  • In the last 5 years, Rigel Pharmaceuticals' Income towards Parent Company had a median value of -$5.7 million in 2023 and averaged $781473.7.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Income towards Parent Company crashed by 16953.21% in 2022 and then surged by 588766.99% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$22.6 million in 2021, then skyrocketed by 106.2% to $1.4 million in 2022, then tumbled by 47.39% to $737000.0 in 2023, then skyrocketed by 1843.28% to $14.3 million in 2024, then soared by 94.81% to $27.9 million in 2025.
  • Its Income towards Parent Company was $27.9 million in Q3 2025, compared to $59.6 million in Q2 2025 and $11.4 million in Q1 2025.